It just so happens that I have brother in law who is
It just so happens that I have brother in law who is visiting this week. He has worked for BP(GSK, etc) in running drug trials and currently works for a small pharmaceutical company running cancer trials.
I told him I was investing money in a small company that is working on a mTNBC drug. That is close to us as many of you know, my wife(his sister) had breast cancer 4 years ago.
I asked him about the 2 mTNBC press releases from this morning and in July.. He read thru them and said--IF this is accurate, this is ground breaking. His quote was "most new drugs--if you get a 30-40% improvement in PFS, that is huge". At first blush the LL trial is talking 10-15X that .
Here were a couple of more of his thoughts:
BTD=a direct conduit to the FDA in regards to LL. It doesn't mean it is going to be approved or Drs are able to use LL but it in theory, BTD makes it easier to get the drug approved by the FDA as there is a lot of direct conversations that happen and the FDA has agreed that this drug has potential.
His company has multiple drugs right now that are classified as BTD--so he is very familiar with it. He said that CYDY still needs a larger trial size to prove that it works and needs to prove to the FDY WHY it works. I hope that they can do both. I talked with him about the no SAE and that it has been proven over the years with the HIV trials. Again, he said that was very important.
The 2nd thing that came out of his mouth was--do they have enough money to run a larger trial. If they do--great, but from the press releases, his thought was that CYDY is setting itself up to either one of 3 things--in no particular order
1. Partnership
2. Merger
3. Buyout
He is back in the mid-west on vacation until the weekend and is going to visit the CYDY website to learn more about LL, watch the Dr Kelly video, read up on it etc. He said he was familiar with a couple of Drs on the SBofA and that was a positive he thought for the company.
He is familiar with CCR5 and is going to talk with some pharmacologist friends in the industry to get their thoughts when he gets back to work next week.
The longest post of mine EVERY and I do believe it was very interesting to talk with him this morning. I'll keep everyone posted on anymore of his thoughts after he does some research.
NJ
47
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Turning the Tide on Pharmacy Costs The world of pharmacy benefits is getting a long-overdue shake-up, courtesy of a new rule mandating transparency from the pharmacy benefit managers (PBMs). This ain't your everyday administrative tweak—it's a seismic shift for the 136 million Americans tied into employer-sponsored health plans. Thanks to the U.S. Department of Labor...
Continue Reading
A Fresh Start for Peapack-Gladstone's Corporate Relic Dust off the pages of history—Peapack-Gladstone's old Pfizer/Beneficial Finance campus is getting a makeover, and boy, it’s not your run-of-the-mill renovation. We're talking adaptive reuse to the tune of nearly $200 million, morphing this architectural gem into CopperWood Senior Living. With all the office...
Continue Reading
Building Resilience on Florida's Shores If you've ever had your eyes on some beachfront real estate down in Florida, you'd know it's not all sandy beaches and sunsets. It's a constant battle against the elements, my friends. The Sage Longboat Key condominiums in Sarasota have taken this challenge head-on with some serious innovation. The Condominium Dream Sitting pretty...
Continue Reading
Anticipation Builds Around Evotec's Q3 2026 Results It's that time again when everyone's tightening their belts in anticipation of another earnings feed. On November 5, Evotec SE is dropping their results for the first nine months of this whirlwind year. Right out of Germany, Hamburg, they're gearing up for a webcast and conference call where all eyes, or should I say...
Continue Reading
Measuring Productivity Goes Beyond Manufacturing Robots aren't just assembly-line tools anymore. In Shanghai, AGIBOT dropped a bombshell at their Innovation Day event: the introduction of Worken, a framework that turns the spotlight on robots' real-world task performance over mere numbers on a production line. Breaking Down Worken Worken, a mash-up of 'Work' and 'Token,'...
Continue Reading
FirstEnergy Foundation's Commitment Shines Bright Alright, here's the scoop. FirstEnergy Foundation isn't just about keeping the lights on anymore. They're throwing down $620,000 to tackle one hell of a tough nut—shelter and stability. This latest infusion spreads across five states, with ten nonprofit warriors in New Jersey alone locking in $120,000 of that pot for...
Continue Reading
Fast Lane Promotion for Chertova It's not every day you see a path from intern to senior analyst paved in just three years. But Anastasia Chertova has pulled off exactly that at New England Consulting Partners (NECP). From crunching numbers as an intern to headlining projects in front of the C-Suite, she's made quite the mark. The kind of trajectory most folks just...
Continue Reading
An Offbeat Choice for Chair? So, Sobi's gone and picked Börje Ekholm as the proposed Chair of their Board. Now, this might raise some eyebrows out there—Ekholm's no stranger to top roles, having steered the ship at Ericsson. The twist here is usually these Chair announcements hum along without much fanfare, but chuck in Ekholm and you get a bit of buzz—probably...
Continue Reading
Max Stock's Q3 Earnings Anticipation Ah, it’s that time again—when we wait with bated breath for another round of quarterly earnings. Max Stock Ltd. (TASE: MAXO) is prepping to spill the beans on their third quarter 2026 performance, with a conference call scheduled for November 17. Big day? You bet. Who's Leading the Call? The brains behind the operation, CFO Paz Oz...
Continue Reading
Nailing Label Precision in Real Time The label printing game just got a major new player. MSM Solutions is rolling out its PortalTrack Print Quality Inspection, and it's not just another tool in the shed—this thing's promising to cut down on label errors before they can bite. Imagine turning your good old industrial label printers into sharp-eyed inspectors, thanks to...
Continue Reading
Top 5 Most Recently Viewed Articles
Euronext Reports Impressive Trading Volumes for October 2025 As the leading European capital market infrastructure, Euronext has made headlines by announcing its trading volumes for the month of October 2025. The announcement is crucial, as it provides insights into market trends and investor activities across its multiple exchanges. Overview of Trading Volumes During the...
Continue Reading
Overview of Amaroq Minerals' Voting Rights Amaroq Minerals Ltd., an independent corporation focused on mine development, is making significant strides in the gold and strategic minerals sector with its extensive land holdings in Southern Greenland. The company has recently announced notable updates concerning its total voting rights and the issuance of shares. Recent...
Continue Reading
Ramaco's Panel Discussion: A Market Indicator? Mark your calendars, because Ramaco Resources is stepping into the limelight at the StoneX Fourth Annual Natural Resources Summit in New York City. You’ve got Jeremy Sussman, the CFO, gearing up to hit the stage and chew over the state of the steel and metallurgical coal markets. With the summit running from June 9 to 10,...
Continue Reading
Challenges in the German Labor Market Recent research has unveiled that German companies are showing a marked reluctance to hire new staff, reaching the lowest level of employment motivation seen in over four years. The data, derived from the Ifo institute, underscores the prevailing challenges in Europe's largest economy. Decline in Hiring Intentions The Ifo employment...
Continue Reading
Cohen & Steers Advances Retail Investments Cohen & Steers Income Opportunities REIT, Inc. (CNSREIT) has taken a significant step forward in its investment strategy by acquiring Village on Pooler Parkway, a community shopping center designed for open-air shopping. This move highlights CNSREIT's dedication to investing in high-quality, necessity-driven retail spaces located...
Continue Reading